RxDoctor Payments Data

Suja Sadasivan, MD

Neurology · Brighton, MANPI 1881822021

Payments from drug & device makers

$65,285in general payments, 2019–2025

Across 623 payments — averaging $104.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$28K
  • Amneal Pharmaceuticals LLC$17K
  • Biohaven Pharmaceutical Holding Company Ltd.$6K
  • Biohaven Pharmaceuticals, Inc.$5K
  • Boston Scientific$2K
  • MDD US Operations, LLC$1K
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$49,21175%
  • Travel & lodging$2,9184%
  • Food & beverage$11,47018%
  • Education$1,6863%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,285 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$65,336
Medicare patients
143
Services billed
1,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$163,746
BotoxOnabotulinumtoxina18$22,114
UbrelvyUbrogepant13$21,281
Aimovig AutoinjectorErenumab-Aooe17$14,123
QuliptaAtogepant11$11,827
Emgality PenGalcanezumab-Gnlm12$9,628
OngentysOpicapone12$6,941
Carbidopa-LevodopaCarbidopa/Levodopa153$5,823
Memantine Hcl76$4,519
Carbidopa-Levodopa ErCarbidopa/Levodopa94$3,979
AmantadineAmantadine Hcl46$3,101
Rasagiline Mesylate12$1,504
Gabapentin32$1,364
RivastigmineRivastigmine Tartrate12$892
Ropinirole Hcl13$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$466$170,68732 claims
AbbVieBotox, Ubrelvy, Qulipta$27,813$55,22242 claims
Upsher-smith Laboratories LLCTopiramate$228$48639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 761 neurology providers in Massachusetts.

Other neurology in Brighton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →